JPRN-jRCT2080223709已完成1 期
A Multiple-Ascending Dose Study in Japanese Patients With Type 2 Diabetes Mellitus to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3298176
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 49
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 70age old（—）
- 性别
- All
入选标准
- •Have T2DM controlled with diet and exercise alone or are stable on a single oral antidiabetic medication (metformin or dipeptidyl peptidase [DPP]-IV inhibitors)
- •- Have a body mass index of 20.0 to 35.0 kilograms per square meter, inclusive
排除标准
- •- Have known allergies to LY3298176, glucagon-like peptide (GLP)-1 analogs, or related compounds
- •- Have had more than 1 episode of severe hypoglycemia, as defined by the American Diabetes Association criteria, within 6 months before entry into the study or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
- •- Have an abnormality in the 12-lead electrocardiogram at screening that, in the opinion of the investigator, increases the risks associated with participating in the study
- •- Have a history or presence of pancreatitis or gastrointestinal (GI) disorder or any GI disease which impacts gastric emptying or could be aggravated by GLP-1 analogs or DPP-IV inhibitors
研究者
相似试验
进行中（未招募）
1 期
A Phase 1/2 Study of ACN00177 in Subjects With Homocystinuria Due to Cystathionine ß-Synthase (CBS) DeficiencyHomocystinuria Due to Cystathionine ß-Synthase (CBS) DeficiencyMedDRA version: 20.0Level: PTClassification code 10020365Term: HomocystinuriaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2019-004791-19-GBAeglea Biotherapeutics, Inc.25
已完成
不适用
Japanese multicenter study of short- and long-term efficacy and safety of itraconazole in the treatment of chronic necrotizing pulmonary aspergillosisChronic Necrotizing Pulmonary AspergillosisJPRN-UMIN000001727Department of Clinical infectious Diseases, School of Medicine, Showa University100
未知
1 期
ONO-4474-03Knee OsteoarthritisJPRN-jRCT2080223824ONO PHARMACEUTICAL CO.,LTD.124
进行中（未招募）
3 期
An extension study for seven patients in Japan with neuromyelitis optica spectrum disorder who completed the open-label period of study CD-IA-MEDI-551-1155 of InebilizumabJPRN-jRCT2051210017Sato Toshiyuki7
未知
1 期
A Two-Part Study in Japanese Patients With Advanced or Metastatic NSCLC. Open-Label Phase I to Assess the Safety & Tolerability of AZD2171 in Combination With Pac/Carb, Then a Phase II, Randomised, Double-Blind Study to Assess the Efficacy of AZD2171 Alone and in Combination With AZD2171 and Pac/CarbCarcinoma, Non-Small-Cell LungJPRN-jRCT2080220478AstraZeneca